Gotham Asset Management LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 9,684 shares of the biopharmaceutical company’s stock, valued at approximately $772,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. Nexthera Capital LP purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $8,375,000. Janus Henderson Group PLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $53,226,000. Farallon Capital Management LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $15,952,000. PDT Partners LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $23,537,000. Finally, QS Investors LLC grew its holdings in Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 900 shares during the period. Institutional investors own 94.25% of the company’s stock.
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) traded up 4.74% during trading on Friday, hitting $119.92. The company’s stock had a trading volume of 1,459,095 shares. The company’s market capitalization is $11.00 billion. Alnylam Pharmaceuticals, Inc. has a 1-year low of $31.38 and a 1-year high of $126.16. The firm’s 50 day moving average is $107.11 and its 200-day moving average is $81.44.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The business had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. During the same quarter in the previous year, the company earned ($1.05) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.20) EPS for the current fiscal year.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 85,316 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total value of $10,664,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the sale, the president now owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.
Several analysts have commented on the company. Goldman Sachs Group, Inc. (The) upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $62.00 to $163.00 in a report on Monday, October 2nd. Chardan Capital restated a “buy” rating and issued a $124.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, September 25th. Jefferies Group LLC lifted their price target on Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, September 26th. Needham & Company LLC boosted their target price on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, September 20th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $116.00 target price (up previously from $110.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 20th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $100.80.
ILLEGAL ACTIVITY NOTICE: “Gotham Asset Management LLC Invests $772,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/gotham-asset-management-llc-purchases-new-stake-in-alnylam-pharmaceuticals-inc-alny.html.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.